Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Non-Current Liabilities (2016 - 2023)

Vistagen Therapeutics' Total Non-Current Liabilities history spans 11 years, with the latest figure at $3.6 million for Q3 2023.

  • For Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $3.6 million; the TTM value through Sep 2023 reached $3.6 million, changed N/A, while the annual FY2021 figure was $12.1 million, 38.75% up from the prior year.
  • Total Non-Current Liabilities for Q3 2023 was $3.6 million at Vistagen Therapeutics, down from $4.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $12.7 million in Q3 2020 and bottomed at $3.6 million in Q3 2023.
  • The 4-year median for Total Non-Current Liabilities is $8.7 million (2020), against an average of $8.9 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 153.39% in 2019 before it crashed 66.85% in 2021.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $8.5 million in 2019, then surged by 47.01% to $12.5 million in 2020, then plummeted by 66.85% to $4.1 million in 2021, then dropped by 12.0% to $3.6 million in 2023.
  • Per Business Quant, the three most recent readings for VTGN's Total Non-Current Liabilities are $3.6 million (Q3 2023), $4.1 million (Q2 2023), and $4.1 million (Q4 2021).